Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|May 15, 2023

Overview and Prevalence of Acne Vulgaris

Author(s)Christopher G. Bunick, MD, PhD

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.

Episodes in this series

EP. 1 Expert Perspectives on a Recent Approval in Acne Management

EP. 1 Expert Perspectives on a Recent Approval in Acne Management

EP. 2 Treatment Selection Considerations for Mild to Moderate Acne

EP. 2 Treatment Selection Considerations for Mild to Moderate Acne

EP. 3 Unmet Needs and the Role of Consensus Guidelines in Acne Management

EP. 3 Unmet Needs and the Role of Consensus Guidelines in Acne Management

EP. 4 Future Directions and Practice Pearls for the Management of Acne

EP. 4 Future Directions and Practice Pearls for the Management of Acne

EP. 5 Expert Perspective on Tailoring Acne Treatments

EP. 5 Expert Perspective on Tailoring Acne Treatments

EP. 6 Skin Care Regimens for Acne Treatment

EP. 6 Skin Care Regimens for Acne Treatment

EP. 7 Acne Treatment Selection Considerations

EP. 7 Acne Treatment Selection Considerations

EP. 8 Overview of Isotretinoin Use and Indication in Acne Management

EP. 8 Overview of Isotretinoin Use and Indication in Acne Management

EP. 9 Expert Perspective on Available Isotretinoin Formulations

EP. 9 Expert Perspective on Available Isotretinoin Formulations

EP. 10 Expert Recommendations for Setting and Managing Acne Treatment Goals with Patients

EP. 10 Expert Recommendations for Setting and Managing Acne Treatment Goals with Patients

EP. 11 Overview of Acne Causes and Triggers

EP. 11 Overview of Acne Causes and Triggers

EP. 12 Considerations for Generic vs Brand Acne Treatment Formulations

EP. 13 Expert Perspectives on Acne Causes and Triggers

EP. 13 Expert Perspectives on Acne Causes and Triggers

EP. 14 Overview of Isotretinoin MOA and Utilization

EP. 14 Overview of Isotretinoin MOA and Utilization

EP. 15 Frontline Forum Part 1: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 15 Frontline Forum Part 1: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 16 Frontline Forum Part 2: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 16 Frontline Forum Part 2: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 17 Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 17 Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 18 Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 18 Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 19 Expert Perspective on the Management of Acne

EP. 19 Expert Perspective on the Management of Acne

EP. 20 Treatment Selection in Patients with Acne Vulgaris

EP. 20 Treatment Selection in Patients with Acne Vulgaris

EP. 21 Differences in Isotretinoin Formulation

EP. 21 Differences in Isotretinoin Formulation

EP. 22 Expert Perspective on the Utilization of Clascoterone Cream 1%

EP. 22 Expert Perspective on the Utilization of Clascoterone Cream 1%

EP. 23 Utilization of Isotretinoin in Patients with Severe Acne

EP. 23 Utilization of Isotretinoin in Patients with Severe Acne

EP. 24 Expert Insights into the Safety of Isotretinoin

EP. 24 Expert Insights into the Safety of Isotretinoin

EP. 25 Overview and Prevalence of Acne Vulgaris

EP. 25 Overview and Prevalence of Acne Vulgaris

EP. 26 Approaches to Target Sebum Production

EP. 26 Approaches to Target Sebum Production

EP. 27 Expert Insights into the Use of Isotretinoin

EP. 27 Expert Insights into the Use of Isotretinoin

EP. 28 Advances in Acne Management

EP. 28 Advances in Acne Management

EP. 29 Expert Opinion on the Utility of Guidelines in Patient Care

EP. 29 Expert Opinion on the Utility of Guidelines in Patient Care

EP. 30 Novel Approach to Sebum Production

EP. 30 Novel Approach to Sebum Production

EP. 31 Expert Insights into the Importance of Active Components in Acne Treatments

EP. 31 Expert Insights into the Importance of Active Components in Acne Treatments

EP. 32 Frontline Forum Part 1: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 32 Frontline Forum Part 1: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 33 Frontline Forum Part 2: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 33 Frontline Forum Part 2: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 34 Frontline Forum Part 3: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 34 Frontline Forum Part 3: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 35 Frontline Forum Part 4: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 35 Frontline Forum Part 4: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 36 Discovering Dermatology Times: August 2023 Acne Vulgaris Supplement

EP. 36 Discovering Dermatology Times: August 2023 Acne Vulgaris Supplement

EP. 37 Top 5 Clinical Pearls for Acne Vulgaris Management

EP. 37 Top 5 Clinical Pearls for Acne Vulgaris Management

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China

ByMarie Bosslett, Assistant Editor

February 3rd 2026

Fractional CO₂ Resurfacing Improves Acne Scarring in Middle Eastern Patients

ByMaddi Hebebrand, MC, Associate Editor

February 2nd 2026

Dermatology Times Spot Test: February 1, 2026

ByMarie Bosslett, Assistant Editor

February 1st 2026

On the Horizon: Innovations in the Acne Treatment Pipeline

ByHeidi Anne Duerr, MPH

January 28th 2026

New Research Highlights Significant Knowledge Gaps in Patients Using Oral Acne Medication

ByMarie Bosslett, Assistant Editor

January 21st 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA